insights_auto
Why is EDIT up ၃.၀၉%?
Dive Deeperchevron_right
EDIT:NASDAQ
Editas Medicine Inc
၂.၈၄ US$
arrow_upward
+၃.၀၉%(+၀.၀၈၅) 1D
အောက် ၈, GMT-၄ ၁၄:၄၈:၅၅ · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for EDIT...
Open
၂.၇၉ US$
High
၂.၉၄ US$
Low
၂.၆၉ US$
Mkt. cap
၄၃.၅၄ ကုဋေ
Avg. vol.
၂.၈၈ သန်း
Volume
၃.၈၇ သန်း
52-wk high
၄.၃၃ US$
52-wk low
၁.၆၆ US$
EPS
-၀.၇၄ US$
Beta
၂.၀၀
Shares outstanding
၁၅.၃၆ ကုဋေ
No. of employees
၈၇
Open
၂.၇၉ US$
High
၂.၉၄ US$
Low
၂.၆၉ US$
Mkt. cap
၄၃.၅၄ ကုဋေ
Avg. vol.
၂.၈၈ သန်း
Volume
၃.၈၇ သန်း
52-wk high
၄.၃၃ US$
52-wk low
၁.၆၆ US$
EPS
-၀.၇၄ US$
Beta
၂.၀၀
Shares outstanding
၁၅.၃၆ ကုဋေ
No. of employees
၈၇
News stories
From web sources and news partners
Yahoo Finance
·
ပြီးခဲ့သည့် ၁ နာရီ
Editas Medicine Gets Clearance For First Human Trial Of Gene-Editing Drug – Wells Fargo Sees Potential For Major Value Upside In 2027
MarketBeat
·
ပြီးခဲ့သည့် ၂ နာရီ
Editas Medicine (NASDAQ:EDIT) Raised to Overweight at Wells Fargo & Company
TipRanks
·
ပြီးခဲ့သည့် ၇ နာရီ
Editas wins approval to launch EDIT-401 Strive trial
Stock Titan
·
ပြီးခဲ့သည့် ၇ နာရီ
An experimental gene-editing drug kept monkeys' bad cholesterol about 90% lower for 10 months
Profile
Editas Medicine, Inc., is a clinical-stage biotechnology company which is developing therapies for rare diseases based on CRISPR gene editing technology. Editas headquarters is located in Cambridge, Massachusetts and has facilities in Boulder, Colorado. Wikipedia
About Editas Medicine Inc